Stocks Comparison
Astrazeneca vs Bristol Myers Squibb: revenue, profit, margins and growth compared
Astrazeneca brought in $58.7B of revenue in fiscal 2025, Bristol Myers Squibb $48.2B in fiscal 2025. Revenue changed by +8.6% at Astrazeneca and -0.2% at Bristol Myers Squibb on the year before, so Astrazeneca grew faster. Astrazeneca kept 17.4% of its revenue as net profit, Bristol Myers Squibb 14.6%. Free cash flow was $11.8B at Astrazeneca and $12.8B at Bristol Myers Squibb.
Side by side, latest fiscal year
| AZN | BMY | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $58.7B | $48.2B |
| Revenue growth | +8.6% | -0.2% |
| Net income | $10.2B | $7.1B |
| Net margin | 17.4% | 14.6% |
| Free cash flow | $11.8B | $12.8B |
| Free cash flow margin | 20.0% | 26.7% |
| Earnings per share (diluted) | $6.54 | $3.46 |
| Cash | $5.7B | $10.2B |
| Debt | $29.6B | $44.8B |
| Price to earnings | n/a | 18.2 |
| Market value | $258.3B | $128.4B |
| Dividend yield | n/a | 3.96% |
| Rank by revenue in sector | #15 of 523 · Health care | #16 of 523 · Health care |
Over the years
Questions about Astrazeneca and Bristol Myers Squibb
Which is bigger by revenue, Astrazeneca or Bristol Myers Squibb?
Astrazeneca is bigger by revenue: $58.7B in fiscal 2025, against $48.2B for Bristol Myers Squibb in fiscal 2025.
Which keeps more of its revenue as profit, Astrazeneca or Bristol Myers Squibb?
Astrazeneca had a net margin of 17.4% in fiscal 2025; Bristol Myers Squibb had 14.6% in fiscal 2025.
Which grew revenue faster, Astrazeneca or Bristol Myers Squibb?
In their latest fiscal years revenue changed by +8.6% at Astrazeneca and -0.2% at Bristol Myers Squibb.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.